trending Market Intelligence /marketintelligence/en/news-insights/trending/e8CPviwU3anH8OCCRZKrwg2 content esgSubNav
In This List

China conditionally approves Becton Dickinson, Bard deal

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


China conditionally approves Becton Dickinson, Bard deal

China's ministry of commerce conditionally approved Becton Dickinson and Co.'s acquisition of C. R. Bard Inc., Reuters reported.

Becton Dickinson is required to sell its global core needle biopsy devices business and a tissue marker product under development as part of the approval.

Becton Dickinson said it plans to sell the soft tissue core needle biopsy product line to Merit Medical pending approval from Chinese authorities.

The U.S. Federal Trade Commission recently approved the $24 billion acquisition on the condition that the companies divest two product lines.

The Chinese approval was the last in a series of regulatory approvals required to close the acquisition.